



Press Release

TxCell participates at two Key US Life Sciences Events:

2014 French Life Sciences Day, New York, US

2014 BIO International Convention, San Diego, US

Valbonne, France, June 18, 2014. – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it will participate at two key life science upcoming events in the United States in June 2014.

French Life Sciences Days in New York, on June 25-26, 2014

This event is organized by France Biotech, of which Damian Marron, CEO of TxCell, has recently been elected Board Member. It aims to bring together French Life Sciences companies listed on stock market with the North American financial community.

During this event, TxCell and 18 other French biotechnology and medical technology companies listed on the French stock market, will present and hold face-to-face meetings with specialized North American investments funds, banks, financial analysts and media.

TxCell will attend the gala dinner, held at Lafayette Restaurant ST, New York at 6:30pm on Wednesday, June 25 with companies and investments fund representatives.

The investor's conference will be held at W Hotel, 541 Lexington Avenue New York on Thursday, June 26. Damian Marron, CEO, TxCell will present the TxCell ASTRiA technology platform and their personalized cellular immunotherapy programs for the treatment of several severe chronic inflammatory and autoimmune diseases.

"This is an excellent occasion for TxCell to present our company to North American investors to raise their interest in the future of TxCell and its innovative product

candidates," said Damian Marron, CEO TxCell. "France Biotech is to be praised for this new initiative and I am proud to have been elected to its Board, where I look forward to playing an active role in supporting the rapidly maturing innovative French life sciences sector."

BIO International Convention in San Diego, on June 23-26, 2014

The convention is an important annual business development forum for biotechnology quoted companies like TxCell. The convention allows access to high-level executives and influential decision makers attending BIO to liaise with key players in the industry, form partnerships, and evaluate emerging technologies.

TxCell has numerous one-to-one partnership meetings booked to discuss its proprietary technologic platform ASTrIA, which enables the development of different personalized Ag-Treg products for many of the severe chronic autoimmune inflammatory diseases.

TxCell will also be participating actively in the exhibition zone of the BIO Convention, at Booth 2917, Hall A in the France Pavilion.

About TxCell

TxCell is developing innovative personalized cell-based immunotherapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary ASTrIA technology platform based on the properties of autologous antigen-specific regulatory T lymphocytes (Ag-Tregs). The company has completed a phase I/IIa study of its lead product candidate, Ovasave® in refractory Crohn's disease patients and has reported good tolerability and positive clinical efficacy. The company plans to initiate a phase IIb study in the same patient population. TxCell has a strategic partnership for Ovasave with the Swiss company Ferring International Center. Listed on Euronext-Paris, TxCell, a spin-off of Inserm (France's National Institute for Health and Medical Research) is located in the Sophia Antipolis technology park, Nice, France. The company has 38 employees based at its headquarters and at its manufacturing site in Besançon. For more information, please visit www.txcell.com

Practical Information about TxCell shares:

ISIN code	FR0010127662
Ticker code	TXCL

About France Biotech

France Biotech brings together French life science companies and their expert partners. Its mission is to support the development of the French life sciences by working for a favorable legislative and fiscal environment. France Biotech catalyzed the French government's creation of a special fiscal status for start-ups in 2004 and continues to act as an advocate for this innovative sector. The organization is currently chaired by Pierre-Olivier Goineau, Co-Founder and CEO of ERYTECH Pharma. France Biotech has over 150 members and is governed by a Board of 20 life science entrepreneurs.

About BIO

BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated.

CONTACTS

TxCell BD & Communication Department Tel: +33(0) 497 218 300 Fax: +33(0) 493 641 580 contact@txcell.com	Image Box – Press relations Neil Hunter / Emma Marshall Tel: +44(0) 20 8943 4685 emma.marshall@imageboxpr.co.uk neil.hunter@imageboxpr.co.uk	NewCap – Investor relations Julien Perez / Pierre Laurent Tel: +33 (0)1 44 71 98 52 txcell@newcap.fr
--	---	--